Chemical formula: C₂₂H₁₉ClO₃  Molecular mass: 366.837 g/mol  PubChem compound: 74989

Therapeutic indications

Atovaquone is indicated for:

Mild to moderate pneumocystis pneumonia caused by Pneumocystis jiroveci

Population group: only adults (18 - 65 years old)

Atovaquone is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP, caused by Pneumocystis jiroveci, formerly classified as P. carinii) (alveolar – arterial oxygen tension difference [(A-a) DO2] ≤45 mmHg (6 kPa) and oxygen tension in arterial blood (PaO2) ≥60 mmHg (8 kPa) breathing room air) in patients who are intolerant of co-trimoxazole therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.